Multidrug chemotherapy for CRC treatment is often supported by the administration of bevacizumab (Avastin®, targeting VEGF), or either cetuximab (Erbitux®) or panitumumab (Vectibix®, targeting EGFR), both positively correlated with improved survival in KRASWT CRC [3, 4]. Here, EGFR is linked to colorectal carcinoma.